An Open Label study of the drug denosumab in acute Diabetes Charcot’s Neuroarthropathy.

This study is testing whether the drug denosumab can reduce bone loss in the feet of people with diabetes who have Charcot foot — a serious condition where bones in the foot weaken and can fracture or collapse. Researchers hope that by stopping bone loss, the Charcot process might resolve more quickly. You may be eligible if: - You are between 18 and 85 years old - You have Type 1 or Type 2 diabetes - You have diabetic peripheral neuropathy (nerve damage in your feet) - You have been diagnosed with acute Charcot foot You may NOT be eligible if: - You are pregnant, breastfeeding, or a woman of childbearing age not using contraception - You have peripheral vascular disease (poor blood flow to the legs/feet) without successful treatment - You have a serious foot ulcer, infection, or bone infection (osteomyelitis) in the affected foot - You have low calcium or vitamin D deficiency - You have significant kidney, liver, or heart failure - You have inflammatory arthritis or bowel disease - You have had a tooth extraction, dental implant, or jaw surgery within the last 3–6 months, or have multiple dental cavities - You have received denosumab in the past 12 months Talk to your doctor about whether this trial might be right for you.